Latest news with #STEP2
Finextra
23-05-2025
- Business
- Finextra
RT1 and STEP2 participants across 14 countries to adopt EBA's VOP solution
EBA CLEARING announced today that over 55 RT1 and STEP2 Participants across 14 countries are preparing to adopt its Fraud Pattern and Anomaly Detection (FPAD) Verification of Payee (VOP) solution to deliver VOP checks in compliance with the Instant Payments Regulation (IPR). 1 This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author. These participants will connect hundreds of payment service providers (PSPs) across Europe, already representing more than 40% of the traffic in STEP2 and RT1. This strong uptake is positioning FPAD as the leading pan-European VOP solution and building up significant reach for VOP across Europe in preparation for the upcoming IPR deadline in October 2025. At the same time, a new release of the VOP functionality has been delivered in May 2025. With this release, EBA CLEARING has integrated the European Payments Council (EPC)'s Directory Service (EDS) into its VOP offering and aligned its VOP interface with the EPC application programming interface (API). To ensure maximum flexibility and choice for PSPs, the release has further enriched the solution with additional requesting and responding options. It has also extended the available connectivity options, including managed connectivity over SWIFTNet and SIANet. Developed with the support and input from fraud experts across EBA CLEARING's multinational user community, the VOP solution builds on FPAD's capabilities to offer flexible options for both sending and receiving VOP checks. FPAD VOP reach will be significant amongst STEP2 and RT1 users and complemented with the EPC VOP Scheme reach. This will allow PSPs to evolve their VOP strategies over time while ensuring pan-European reach from day one. By using FPAD for VOP, PSPs can meet compliance requirements, reduce user friction and strengthen their fraud risk management. Dr. Patrik Pohl, Managing Director, Head of Corporate Cash Management Germany at Deutsche Bank, said: 'FPAD VOP stands out by going beyond standard VOP checks. We will be able to enrich account checks with additional FPAD indicators, which offer deeper insights to help us prevent fraud and avoid unnecessary friction for our corporate customers. With distinct user needs driving the design and development of FPAD, EBA CLEARING has delivered a comprehensive set of VOP solutions that provides stronger results, greater security and an improved client experience.' Sophie Giorgi, Head of Payment System and Infrastructure Relationships at Crédit Agricole Payment Services, said: 'For us, FPAD VOP is the best solution for cross-border transactions and provides a reliable back-up. What is more, with FPAD, we are not only getting a scheme-compliant, IPR-compliant VOP solution, but also access to a fully-fledged fraud detection solution leveraging a pan-European network view.' Tanja Konrad, Head of Daily Banking Services at Erste Group, said: 'Thanks to the pan-European approach and coverage of FPAD VOP, we will be able to roll out a single VOP solution across our network of banks in Central and Eastern Europe. We look forward to combining the VOP check with other FPAD indicators to strengthen our risk controls, while also making the VOP experience as smooth as possible for our customers.' Erwin Kulk, Head of Service Development and Management at EBA CLEARING, said: 'FPAD VOP is real and ready. PSPs have ample time to introduce the mandatory VOP in all their channels. By providing options and choice, we will be servicing a diverse and large group of PSPs. This formula has proven its value in operating pan-European market infrastructures. The broad adoption that FPAD VOP is already seeing today demonstrates the importance of a not-for-profit, user-driven approach to solve infrastructure challenges in the SEPA ecosystem.' EBA CLEARING's FPAD functionality was developed in 2023 with the support of fraud experts from STEP2 and RT1 Participants across Europe, following the release of a blueprint and subsequent RT1 and STEP2 user consultation in Q4 2022. STEP2 and RT1 are pan-European retail payment systems processing SEPA Credit Transfers and Direct Debits (STEP2) and SEPA Instant Credit Transfers (RT1) respectively. Both systems are operated by EBA CLEARING, a European-owned, European-governed and European-overseen financial market infrastructure provider providing cost-effective solutions to the SEPA payments ecosystem.
Yahoo
08-05-2025
- Business
- Yahoo
ArbitrumDAO Selects Franklin Templeton, Spiko, and WisdomTree for STEP 2 to Expand RWA Adoption On-Chain
NEW YORK, May 8, 2025 /PRNewswire/ -- The Arbitrum Foundation today announces that the ArbitrumDAO has confirmed the next phase of its Stable Treasury Endowment Program (STEP), allocating 35 million $ARB to tokenized U.S. treasury products through leading institutional issuers Franklin Templeton, Spiko and WisdomTree. Launched in July 2024, STEP is the first ArbitrumDAO-driven initiative to deploy treasury capital into tokenized real-world assets at scale. The initial tranche of over $30 million has already generated nearly $700,000 in passive yield for the DAO while advancing the on-chain adoption of institutional-grade assets such as BlackRock's BUIDL, Ondo's USDY, and Mountain Protocol's USDM. Following a robust RFP process that evaluated over 50 submissions, the DAO has approved the following allocations for STEP 2 recipients: 35% to Franklin Templeton's FOBXX (tokenized as BENJI) 35% to Spiko's USTBL 30% to WisdomTree's WTGXX Each issuer offers regulated, tokenized access to short-duration U.S. Treasuries, ensuring both compliance-grade security and on-chain liquidity for Arbitrum's growing treasury reserves. "Having organizations like Blackrock, Franklin Templeton, Spiko, and WisdomTree interacting with a DAO publicly in a forum is an unbelievable accomplishment for the whole crypto space," said Matthew Fiebach, Co-Founder of Entropy Advisors. "Since day one, Arbitrum has been strategically positioned at the heart of crypto's convergence with TradFi, and STEP is a great example of the DAO's steadfast push to continue bringing institutions onchain." The latest allocation underscores STEP's mission to create a yield-bearing, composable, and sustainable treasury. ArbitrumDAO is a leader in real-world asset adoption, with over $45 million deployed across eight issuers and over $240 million in RWAs currently held on Arbitrum-based platforms, representing a more than 50x increase over the past year. Allocated organizations applauded the expansion: "We are thrilled to be selected as a manager for the STEP 2 program, deepening our already strong connection with the Arbitrum user base," said Roger Bayston, Head of Digital Assets at Franklin Templeton. "By leveraging Arbitrum's leading Layer 2 technology, we are able to deliver faster, more scalable, and cost-efficient solutions to our clients. This collaboration not only strengthens our commitment to innovation but also positions us at the forefront of the next generation of financial services infrastructure." "Being selected by the STEP 2 committee is a powerful endorsement of our mission: to deliver secure, regulated, on-chain treasury solutions that are accessible to all, added Paul Adrien, CEO of Spiko. "Since launching the first tokenized UCITS funds on public blockchains in mid-2024, Spiko has rapidly become Europe's leading tokenization platform, with over $260 million in assets under management. Our ambition is to build the leading treasury management fintech on Arbitrum." "We are honored to be selected as part of Arbitrum's Treasury Diversification initiative," said Maredith Hannon, Head of Business Development, Digital Assets at WisdomTree. "Expanding access to tokenized RWAs is central to our mission, and this opportunity with Arbitrum highlights the growing demand for institutional-grade digital assets. Through WisdomTree Connect, we are bringing trusted, institutional-grade solutions to onchain entities, supporting the next generation of treasury operations built on digital asset infrastructure." Arbitrum's STEP program not only addresses idle capital inefficiencies but also positions the ArbitrumDAO for future diversification into new asset classes, including early-stage ventures, credit strategies, and commodities. To learn more about Arbitrum, please visit About ArbitrumArbitrum is a customizable, interoperable set of solutions designed to bring businesses and people onchain. Its flagship blockchain, Arbitrum One, dominates L2 TVL with deep liquidity and streamlined deployment capabilities, powering dApp innovation across DeFi, DePIN, gaming, and other verticals. Additional technologies like Orbit, which enables the development of customizable, interconnected chains leveraging the Arbitrum technology, and Stylus, supporting Rust and C++, push Arbitrum to the forefront of pioneering innovation in blockchain development. Media ContactGarret J. Shawpr@ View original content to download multimedia: SOURCE Arbitrum Foundation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-05-2025
- Business
- Yahoo
Repare signs out-licensing deal with DCx Biotherapeutics
Repare Therapeutics has entered an out-licensing agreement with Canadian biotechnology firm DCx Biotherapeutics for discovery platforms and intellectual property (IP). Repare will obtain $4m in upfront and near-term payments from DCx, along with a 10% common equity position. This includes certain dilution protection rights. Repare is also qualified for potential upcoming payments related to out-licensing, commercial and clinical milestones, and low-single-digit tiered sales royalties for DCx's specific product development. 20 of Repare's preclinical research employees will be retained by DCx, which will also acquire lease rights to specific laboratory facilities in Montreal, Canada, and equipment. Repare has secured the right to appoint a nominee to DCx's board of directors. The out-licensed platforms from Repare are the SNIPRx platform, which is validated clinically, early discovery-stage platforms SNIPRx-surf and STEP², and other IP. Repare Therapeutics CEO, chief financial officer and president Steve Forte stated: 'We have taken careful steps to evaluate all aspects of our business to ensure continued value generation, and this out-licensing agreement with DCx for our discovery platforms enables us to further focus on our clinical portfolio and drive cost reductions while maintaining an economic interest in the platform technologies we have developed. 'We look forward to reporting initial data from our two ongoing Phase I clinical trials in the second half of 2025, and continue to evaluate partnering and strategic alternatives across our portfolio assets.' The SNIPRx-surf platform is designed to detect cell surface targets in tumours or cancer models, utilising gene expression, protein features and a machine learning algorithm. Repare's SNIPRx platform has been instrumental in developing targeted therapies for genomic instability and DNA damage repair. A chemogenomic discovery platform, STEP2, leverages clustered regularly interspaced short palindromic repeats (CRISPR)-enabled genetic screens with small molecule inhibitors to pinpoint genetic lesions sensitive to these inhibitors. The company's clinical pipeline encompasses RP-3467, RP-1664 and lunresertib. DCx Biotherapeutics is backed by Amplitude Ventures. "Repare signs out-licensing deal with DCx Biotherapeutics" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
National Post
01-05-2025
- Business
- National Post
Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates
Article content Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP 2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates Article content Article content VANCOUVER — DCx Biotherapeutics Corporation ('DCx') today announced an agreement with Repare Therapeutics Inc. ('Repare') (NASDAQ: RPTX) to (i) in-license Repare's discovery platform including certain program intellectual property, (ii) retain talent, (iii) acquire lease rights to laboratory facilities in Montreal and (iv) acquire laboratory equipment (the 'Transaction'). Combining the founding team's deep expertise in biologics innovation and development with the newly acquired discovery and translational capabilities, DCx is uniquely positioned to develop a new class of Multi-Modal Antibody Drug Conjugates ('MM-ADCs') against genetically-defined cancers. Article content DCx Strategy: Article content DCx addresses the root drivers of cancer, genetic mutations that lead to tumor proliferation and survival, by deconvoluting key cellular interdependencies using the MuSic™ platform. Understanding this roadmap enables the mutation-specific drugging of multiple critical targets to synergistically destroy tumors and induce long-term immune memory to achieve durable therapeutic responses while limiting side effects. Unlike current ADCs that deliver broadly chemotoxic payloads to a limited set of antibody targets, DCx's starting strategy is to develop MM-ADCs that optimize the synergy between, and simultaneously target, genetically-defined intracellular and cell-surface targets. The goals for this approach are to (i) increase efficacy, (ii) prolong activity by eliminating escape mechanisms and engaging the immune system, and (iii) improve tolerability while reducing side effects. Article content 'DCx's founding vision is to realize the full potential of antibody drug conjugates by improving on the selectivity, potency, and tolerability for this promising class of therapeutics thus leading to improved clinical outcomes such as progression-free survival and overall survival,' said Ali Tehrani, PhD, Chief Executive Officer of DCx. 'This transaction with Repare is highly synergistic with our expertise and ambitions and accelerates the development of multiple development candidates over the next three years. We are also looking forward to embarking on this journey together with Repare's world-class preclinical research team that is joining the DCx family.' Article content Transaction: Article content DCx acquires rights to Repare's proprietary CRISPR, bioinformatics, and machine learning enabled platforms (now known collectively as the MuSic™ Platform) for the identification of surfaceome targets specific to genetic lesions in tumors DCx obtains non-exclusive license to SNIPRx® and STEP 2 in support of discovering synthetic lethal and other targets DCx acquires undisclosed surfaceome targets ('Acquired Targets') and antibodies discovered by Repare DCx acquires undisclosed small molecule programs from Repare DCx welcomes ~20 scientific and support colleagues spanning expertise in medicinal chemistry, molecular biology, bioinformatics, analytics, and pharmacology DCx acquires lease rights to certain of Repare's Montreal laboratory facility and certain laboratory equipment Article content 'We are excited with the potential in what DCx can bring to develop next-gen antibody drug conjugates and how this Transaction, together with a world-class management and scientific team, can meaningful propel these efforts forward,' comments Jean-François Pariseau, DCx Board Chair and Partner at Amplitude Ventures. Article content Launched out of Amplitude by Partner Ali Tehrani, DCx is the sixth company launched by Amplitude via its innovation platform. As part of this Transaction, Dr. Tehrani will assume the role of CEO. Other co-founders include Drs. David Poon and Ismael Samudio, and Ms. Candice Madalena. Together, they will leverage their deep experience in drug development, including most recently at Abdera and Zymeworks, which recently had the world's first bi-paratopic antibody therapeutic, Ziihera® (zanidatamab), approved by the FDA. Article content The Transaction is effective as of May 1, 2025. In consideration for the Transaction, Repare is eligible to receive, from DCX, the following: Article content Upfront and near-term cash payments, together with equity in DCx and a nominee to DCx's board of directors Out-licensing, clinical, and commercial milestones, as well as low single-digit tiered sales royalties for products developed with Acquired Programs Out-licensing, clinical, and commercial milestones for products developed with Acquired Targets Article content Other financial information is not disclosed. Article content DCx Biotherapeutics is a preclinical-stage discovery and translational company addressing key dependencies of cancer lesions by developing multi-modal synergistic-targeting therapeutics with improved efficacy and tolerability while minimizing resistance. DCx's MuSic™ platform is enabled through the integration of CRISPR-based high-throughput functional screening combined with deep bioinformatics in support of advancing a pipeline of immune-stimulatory precision antibody drug conjugates to improve therapeutic outcomes against genetically-defined cancers. Visit to learn more. Article content Article content Article content Article content Article content Contacts Article content Article content Article content
National Post
01-05-2025
- Business
- National Post
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics
Article content CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. ('Repare') (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation ('DCx'), a newly-launched Canadian biotechnology company developing next generation precision drug conjugates and supported by Amplitude Ventures. Additionally, DCx will retain certain preclinical research personnel, acquire lease rights to certain laboratory facilities in Montreal and acquire certain laboratory equipment. Article content Article content 'We have taken careful steps to evaluate all aspects of our business to ensure continued value generation, and this out-licensing agreement with DCx for our discovery platforms enables us to further focus on our clinical portfolio and drive cost reductions while maintaining an economic interest in the platform technologies we have developed,' said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. 'We look forward to reporting initial data from our two ongoing Phase 1 clinical trials in the second half of 2025, and continue to evaluate partnering and strategic alternatives across our portfolio assets.' Article content Under the terms of the out-licensing agreement, Repare will receive upfront and near-term payments totaling $4 million, as well as a 9.99% common equity position in DCx (including certain dilution protection rights) and is eligible to receive potential future out-licensing, clinical and commercial milestone payments, as well as low-single digit tiered sales royalties for the development of certain products by DCx. Additionally, DCx will retain approximately 20 of Repare's preclinical research employees. Repare has the right to appoint one nominee to the board of directors of DCx. In connection with the transaction, Repare out-licensed its clinically-validated SNIPRx platform and its early discovery-stage SNIPRx-surf and STEP 2 platforms, along with other intellectual property. The SNIPRx-surf platform identifies cell surface targets based on gene expression and protein features in tumors or cancer models, including by clinically relevant biomarkers and machine learning algorithm. The STEP 2 platform is a chemogenomic discovery platform, which uses CRISPR-enabled genetic screens with small molecule inhibitors to identify clinically relevant genetic lesions that are sensitive to small molecule inhibitors. Article content About Repare Therapeutics Inc. Article content Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare has utilized its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Repare's clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit and follow @Reparerx on X (formerly Twitter) and LinkedIn. Article content DCx Biotherapeutics is a preclinical-stage discovery and translational company addressing key dependencies of cancer lesions by developing multi-modal synergistic-targeting therapeutics with improved efficacy and tolerability while minimizing resistance. DCx's MuSic™ platform is enabled through the integration of CRISPR-based high-throughput functional screening combined with deep bioinformatics in support of advancing a pipeline of immune-stimulatory precisiono0 antibody drug conjugates to improve therapeutic outcomes against genetically-defined cancers. Visit to learn more. Article content Forward-Looking Statements Article content This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are 'forward-looking statements. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: Repare's out-license of its discovery platform to DCx; the risk that Repare may not realize the potential benefits of the transaction with DCx; Repare's ability to drive cost reductions while maintaining an economic interest in its assets; the timing, progress and results of Repare's two ongoing Phase 1 clinical trials; and the receipt of milestone payments and royalties under the out-license agreement. These forward-looking statements are based on Repare's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Repare's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and changes in tariffs and trade policies, on Repare's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; Repare's ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause Repare's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled 'Risk Factors' in Repare's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') and the Québec Autorité des Marchés Financiers ('AMF') on March 3, 2025. Repare expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at . Article content Article content Article content Article content Article content Article content
